Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
Pediatric Blood & Cancer2007Vol. 50(4), pp. 799–805
Citations Over TimeTop 10% of 2007 papers
Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard Görlick, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, Catherine A. Billups, Malcolm A. Smith
Abstract
Rapamycin demonstrated broad antitumor activity against the PPTP's in vivo tumor panels, with particularly noteworthy activity for selected sarcoma and ALL xenografts. Future work will evaluate the molecular characteristics of responding models and the activity of combinations of rapamycin with other anticancer agents.
Related Papers
- → Initial Symptoms and Clinical Features in Osteosarcoma and Ewing Sarcoma*(2000)364 cited
- Serum levels of TNF-beta and sTNF-R in patients with malignant bone tumours.(2003)
- → Soluble p185HER-2 in patients with malignant bone tumours(2004)3 cited
- → Heterogeneity of xenografted osteosarcoma: A human sarcoma transplanted into nude mice(1991)2 cited
- → Atypical Cases of Osteosarcoma.(1991)